A Phase I/II Study of TJ004309 for Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a phase I/II study of single drug TJ004309 and PD-1 monoclonal antibody
injection combine treatment for Advanced solid tumor. This study include two stages. First
stage is dose escalation and second stage is dose extension. The purpose of part A is to
confirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safety,
effectiveness, Pharmacokinetics, pharmacodynamics and biomarker properties for effective
subjects.